Dyne Therapeutics Stock Drops After ‘Surprise’ Pivot In Primary Endpoint For Muscle Drug Trial The updated study will enroll 60 participants and track additional measures like muscle strength, mobility, and patient-reported outcomes.
Which stocks are moving on Tuesday? Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Why Is Dyne Therapeutics Stock Trading Lower On Tuesday? Dyne updates DYNE-101 trial timeline, reports strong 12-month data, and receives FDA Breakthrough Therapy status for treating DM1.
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (
NASDAQ:DYN ), focused on developing therapies for ...
Get insights into the top gainers and losers of Tuesday's pre-market session. Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Curious about the stocks that are showing activity after the closing bell on Monday? Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor concerns over data updates.
Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday? Dyne Therapeutics' DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated Approval by 2026.
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful functional improvements.
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results.
Tech Stocks Soar, Treasury Yields Fall On Cool Inflation Data; Starbucks Rockets, Chipotle Plummets: What's Driving Markets Tuesday? A wave of bullish sentiment swept through Wall Street on Tuesday after lower-than-expected producer inflation data solidified expectations for Federal Reserve rate cuts, prompting speculators to increase bets on a more significant 50
DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024 DYN stock results show that Dyne Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
